Navigation Links
Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
Date:4/15/2008

tual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
2. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
3. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
4. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
8. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
9. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
10. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... , The new Dompé website ... concerning the biopharmaceutical Group,s national and international clinical research activities ... recently launched institutional website that is receiving accolades from all ... new chapter in the fascinating story of Drug Discovery   ... hub on the world of clinical research, ranging from information ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today reported ... September 30, 2009. , For the third quarter of 2009, ... per share, compared to a net loss of $37.7 million, ... Weighted average shares outstanding for the third quarters of 2009 ...
... 2 The owner and operator of a Houston-area ... defrauding the Medicare program, announced Assistant Attorney General of ... Johnson of the Southern District of Texas and Daniel ... & Human Services (HHS). , Noel Wayne Jhagroo, 47, ...
Cached Medicine Technology:Rigel Announces Third Quarter 2009 Financial Results 2Rigel Announces Third Quarter 2009 Financial Results 3Rigel Announces Third Quarter 2009 Financial Results 4Rigel Announces Third Quarter 2009 Financial Results 5Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
(Date:12/22/2014)... 2014 Xarelto Lawsuit News : ... judges has granted a request to centralize pending and ... Court, Eastern District of Louisiana. The U.S. Judicial Panel ... 12 to transfer over 50 Xarelto cases–21 lawsuits and ... Louisiana court for consolidation under U.S. District Judge Eldon ...
(Date:12/22/2014)... 2014 Christmas is days away, and last ... and easy solution that will please: the Sublime Gift ... from from $25 up to $350," says Kathy Heshelow, founder ... and a wide array of skin care products and Skin ... expiration dates. , Gift delivery past shipping deadlines, or ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, ... collection , and launched a bamboo flooring promotion with ... until Jan. 30, 2015. , According to the CEO ... bamboo flooring available today; it has a highly distinctive ... hardwoods. Strand woven bamboo is made by a unique ...
(Date:12/21/2014)... 2014 When families in Coral Gables get ... call? The new answer is Lice Troopers . Located ... their newest treatment center will be the new go-to resource ... without the use of harmful chemicals or pesticides. ... 1, 2015. Like the company’s first clinic (located at 1005 ...
Breaking Medicine News(10 mins):Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2
... with care as your parents and loved ones prepare for ... to keep most of familiar traditions that helped define your ... notice that things don,t quite look the same as they ... this holiday checklist from Home Instead Senior Care if you ...
... German . , Chocolate, excitement and the stress ... They are also responsible for triggering migraines in many young ... just as important as getting the right medication. However the ... today stressed that parents and young people need to be ...
... Majority Predict Increase in Consumer-directed Plan Participation , ... Nearly three-quarters of health plan executives expect the current ... than the 2001-2002 downturn, according to a survey released today ... Future: Health Plans Respond to the Financial Crisis." While few ...
... isn,t a new technology, but it,s always finding ... ads in magazines, certain time-release pharmaceuticals, and (perhaps ... , Now Sandia National Laboratories resident microencapsulation ... company to use microencapsulation technology in a novel ...
... PA, 17 December 2008 - Elsevier, world-leading publisher of ... pleased to announce that, beginning in January 2009, the ... ( JPSM ) (http://www.jpsmjournal.com) will be the official ... Medicine (AAHPM). The JPSM will continue ...
... Dec. 17 /PRNewswire/ -- Finesse Solutions, LLC, ... science process applications, announced the introduction of an autoclavable ... requires less maintenance than traditional DO sensors currently used ... "Our new TruDO Optical sensor ushers in next-generation ...
Cached Medicine News:Health News:Does Your Senior Need Help at Home? A Holiday Checklist for Anyone Caring for Seniors 2Health News:Does Your Senior Need Help at Home? A Holiday Checklist for Anyone Caring for Seniors 3Health News:Migraines: Help for a common problem in children and teenagers 2Health News:Health Plan Executives Foresee Continued Decline in Small Business Enrollment, According to CSC Survey 2Health News:Health Plan Executives Foresee Continued Decline in Small Business Enrollment, According to CSC Survey 3Health News:Sandia's microencapsulation project gives local entrepreneur warm glow 2Health News:Sandia's microencapsulation project gives local entrepreneur warm glow 3Health News:Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM 2Health News:Finesse Announces TruDO Optical Autoclavable Sensors for Bioprocess Applications 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: